This article is for educational and research purposes only. Nothing here constitutes medical advice. Consult a licensed healthcare provider before using any peptide or medication.
What Is Tesamorelin?
Tesamorelin (marketed as Egrifta) is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of the 44 amino acids of native GHRH with an added trans-3-hexenoic acid group at the N-terminus for enhanced stability. Developed by Theratechnologies, it was approved by the FDA in 2010 for the reduction of excess abdominal fat (lipodystrophy) in HIV-infected patients — making it the only FDA-approved GHRH analog currently on the market in the United States.
Tesamorelin occupies a unique position in the peptide landscape: it works through the natural GHRH receptor to stimulate endogenous GH production, providing a more physiological approach to GH elevation than direct GH injection. Its FDA-approved status gives it a level of regulatory validation that most research peptides lack.
Mechanism of Action
Tesamorelin's mechanism mirrors that of endogenous GHRH with enhanced pharmacokinetics:
- GHRH receptor binding: Binds to GHRH receptors on anterior pituitary somatotroph cells, activating the cAMP-PKA signaling cascade that stimulates GH gene transcription, synthesis, and secretion.
- Pulsatile GH release: Stimulates the pituitary to release GH in natural pulses, preserving the physiological rhythm and somatostatin feedback regulation — unlike exogenous GH, which suppresses endogenous production.
- IGF-1 elevation: Increases circulating IGF-1 through GH-mediated hepatic production. Clinical trials showed mean IGF-1 increases of 80-120 ng/mL, bringing many patients from below-normal to mid-normal range.
- Visceral fat targeting: The mechanism by which tesamorelin preferentially reduces visceral adipose tissue (VAT) relates to the high density of GH receptors on visceral adipocytes compared to subcutaneous fat. GH stimulates lipolysis in these cells, mobilizing visceral fat stores.
Clinical Trial Evidence
The FDA approval was based on two pivotal Phase 3 trials enrolling HIV-infected adults with lipodystrophy. Over 26 weeks, tesamorelin 2 mg daily reduced trunk fat by approximately 15-18% as measured by CT scan, compared to a 2-5% increase in placebo groups. Visceral adipose tissue specifically decreased by 15-20%. These reductions were accompanied by improvements in trunk appearance and patient-reported body image outcomes.
Beyond the HIV-lipodystrophy indication, research has explored tesamorelin for broader metabolic applications. A study in abdominally obese adults without HIV demonstrated significant VAT reduction (approximately 15%) and improvements in triglycerides and carotid intima-media thickness — a surrogate for cardiovascular risk. Research has also shown tesamorelin reduces liver fat content, with studies demonstrating a 37% relative reduction in hepatic fat fraction in MASLD/NAFLD patients, along with improvements in fibrosis biomarkers.
A notable cognitive study showed that 20 weeks of tesamorelin improved executive function and verbal memory in older adults with mild cognitive impairment and in cognitively normal adults, potentially mediated by IGF-1's neurotrophic effects.
Dosing and Administration
- FDA-approved dose: 2 mg administered subcutaneously once daily
- Injection site: Abdomen, rotated within the abdominal area
- Treatment duration: The FDA label notes that treatment should be discontinued if effects are not maintained, as VAT may reaccumulate after discontinuation
Safety Profile
As an FDA-approved medication, tesamorelin has a well-characterized safety profile from controlled trials. Common side effects include injection site reactions (erythema, pruritus, pain), arthralgia, peripheral edema, and myalgia — effects consistent with GH elevation. IGF-1 levels should be monitored, and the medication carries precautions regarding glucose homeostasis (GH can worsen insulin sensitivity), hypersensitivity reactions, and potential tumor growth stimulation in patients with active malignancies.
The Bottom Line
Tesamorelin is the gold standard among GHRH analogs — FDA-approved, clinically validated, and backed by rigorous Phase 3 trial data. Its demonstrated efficacy for visceral fat reduction, emerging data for liver fat and cognitive function, and physiological mechanism of action (endogenous GH stimulation rather than replacement) make it one of the most evidence-based options in the GH optimization space. As a prescription medication, it requires physician oversight and is indicated specifically for HIV-associated lipodystrophy, though off-label use for metabolic health is growing.